The following video is part of our "Motley Fool Conversations" series in which health-care editor and analyst David Williamson and industrials editor and analyst Brendan Byrnes discuss topics across the investing world.
In today's edition, David and Brendan discuss popular biotech Exelixis. They review the two deals the company brokered in recent weeks and how they will impact Exelixis as it tries to advance cabozantinib in 2012.
Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time thisarticle was published Brendan Byrnes does not own shares of the companies listed above. David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Exelixis and Johnson & Johnson.Motley Fool newsletter services recommendExelixis and Gilead Sciences. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.